AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04044053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fed State
Description: 400 mg MR in fed state
Study NCT04044053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fasted State
Description: 400 mg MR in fasted state
Study NCT01195376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: 3 Intramuscular injections.
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 3 Intramuscular injections
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin.
Description: 3 oral doses.
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin.
Description: 3 oral doses.
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix.
Description: 3 intramuscular injections
Study NCT00344318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix.
Description: 3 intramuscular injections
Study NCT01035515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried blood spot test
Description: Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
Study NCT03666468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Package
Description: Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine test
Description: A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artery ultrasound
Description: Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
Study NCT00793598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00793598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Study NCT03151837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greenyn Momordica charantia extracts
Description: Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
Study NCT03151837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Starch
Study NCT00000383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused CBT
Description: Structured skills, exposure, trauma-specific interventions
Study NCT00000383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-Centered Therapy
Description: Client-directed supportive interventions
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index
Description: Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of advanced glycation-end products
Description: These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening
Description: The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
Study NCT03228459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
Study NCT03666468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Paper Guidelines
Description: Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
Study NCT05769244 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
Study NCT02243332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeStim mobile rehabilitation assistance device
Description: KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
Study NCT03780283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
Study NCT02671396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based intervention
Description: Virtual reality based balance training
Study NCT02671396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Conventional balance training
Study NCT03731611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
Study NCT03228459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Result and recommendation report
Description: A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
Study NCT03228459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
Study NCT01755962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glycemic Load
Study NCT01755962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic Load
Study NCT01755962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Study NCT02340208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
Study NCT03482648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S, Single dose
Description: Single dose of BBT-401-1S, 7 dose levels, oral capsule
Study NCT03482648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S, Multiple doses
Description: Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
Study NCT03482648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to BBT-401-1S, oral capsule
Study NCT03896789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEGASUS Program for Care
Description: This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
Study NCT02921217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Probiotic
Description: Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
Study NCT02921217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inactivated probiotic
Description: Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
Study NCT05769244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
Study NCT05769244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
Study NCT02921217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo: 300 mg maltodextrin.
Study NCT02136641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
Study NCT02136641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam+Fentanyl Combination
Description: Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
Study NCT03008668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study NCT03008668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study NCT02136641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam+Ketamine Combination
Description: Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
Study NCT02540824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib single agent arm
Description: For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
Study NCT01611493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Prevail Implant
Description: Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
Study NCT01611493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Non Prevail Implant
Description: Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
Study NCT00982644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT00982644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT02023346 — intervention group
Intervention type: BEHAVIORAL
Intervention: surveys and cognitive tests
Study NCT02695134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healing Touch
Description: Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
Study NCT04492475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
Study NCT04492475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
Study NCT04492475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study NCT04492475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study NCT05462067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LARA IOL
Description: EDOF IOL for treatment of cataract
Study NCT05462067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LARA IOL
Description: EDOF IOL for treatment of cataract
Study NCT05462067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA Tri IOL
Description: Trifocal IOL for treatment of cataract
Study NCT01756924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102
Study NCT01756924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV or Oral standard of care antibiotics
Study NCT01756924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT01082900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic CPAP Administration
Description: EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room
Study NCT01082900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic CPAP Administration
Description: EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room
Study NCT03665532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Engagement in Services
Description: Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
Study NCT03665532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth Engagement in Services
Description: Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
Study NCT02808182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotinic acid
Description: oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
Study NCT02808182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [7,7,8,8-2H]-palmitate
Description: using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
Study NCT02808182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [U-13C]-palmitate
Description: oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
Study NCT02808182 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
Study NCT02808182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: liquid meal
Description: At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
Study NCT06778369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traingular exclusion technique in mitral valve repair
Description: The prolapsed part of the posterior leaflet is inverted and excluded, not resected toward the left ventricle, and the margins of the prolapsed part are sutured to each other's using proline 5/0, extending from the posterior leaflet edge to the posterior annulus. Then the posterior annulus is reinforced with an annuloplasty band using a treated strip of pericardium. The determination of suitable ring size is subsequently predicated upon the assessment of inter-commissural distance surface area and the anterior leaflet, utilizing sizers that are correlated with typical mitral geometry.
Study NCT04201691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic rehabilitation
Description: The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
Study NCT04201691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic rehabilitation+mobilization
Description: Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
Study NCT00186446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion and smoking cessation behavioral intervention
Study NCT01898754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-ART Oligonucleotide Assay (OLA)
Description: Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
Study NCT03777566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sonohysterography
Description: sonohysterography with measuring the uterine cavity volume
Study NCT04876495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Study NCT04876495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potato protein isolate
Description: Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.